Kinin-like Activities of the Synthetic Low Molecular Weight Fragment of Fibrinogen Degradation Products

Summary

Some biological properties of a synthetic peptide based on an anticoagulant peptide obtained from fibrinogen degradation products by the action of plasmin are reported. This peptide produced smooth muscle contraction without the presence of bradykinin. The contraction caused by this peptide was not modified by atropin (10^-6 g/ml), hyoscine (10^-6 g/ml) and tetrodotoxin (2xl0^-7 g/ml). A hypotensive effect was observed following the intravenous injection of the peptide into an anesthetized rat indicating that this peptide has an action similar to that of bradykinin though less potent.

• References

• 1 Blombäck E. 1964; Chemical aspects of fibrinogen and fibrin. Thrombosis et Diathesis Haemorrhagica, Supplement 13: 29.
• 2 Buluk K, Malofiejew M. 1969; The pharmacological properties of fibrinogen degradation products. British Journal of Pharmacology 35: 79.
• 3 Fletcher A. P, Alkjaersig N, Fisher S, Sherry S. 1966; The proteolysis of fibrinogen by plasmin: The identification of thrombin clottable fibrinogen derivatives with polymerize abnormally. Journal of Laboratory and Clinical Medicine 68: 780.
• 4 Gladner J. A, Murtaugh P. A, Folk J. E, Laki K. 1963; Nature of peptide released by thrombin. Annals of New York Academic Science 104: 47.
• 5 Kowalski W, Kopec M, Wegrzynowicz M. 1964; Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness, and viscous metamorphosis. Thrombosis et Diathesis Haemorrhagica 10: 408.
• 6 Kuriyama H, Tomita T. 1970; Action potential in taenia coli and uterus of guinea pig studied by double sucrose gap method. Journal of General Physiology 50: 147.
• 7 Larrieu M. J, Rigollot C, Marder V. J. 1972; Comparative effects of fibrinogen degradation fragments D and E on coagulation. British Journal of Haematology 22: 719.
• 8 Malofiejew M. 1970; The biological and pharmacological properties of some fibrinogen degradation products. Scandinavian Journal of Haematology, Supplement 13: 303.
• 9 Marder V. J, Shulman N. R, Carrol W. R. 1969; High molocular weight derivatives of human fibrinogen produced by plasmin. Journal of Biological Chemistry 244: 2111.
• 10 McKay D. G. 1965. Disseminated Intravascular Coagulation. Hoeber Medical Publications. Harper and Row; New York.:
• 11 Merrifield R. B. 1963; Solid phase peptide synthesis I. The synthesis of a tetrapeptide. Journal of American Chemical Society 85: 2149.
• 12 Miller S. P, Sachez-Avalos J. 1968; Degradation of fibrinogen by proteolytic enzymes II. Effects of the products on coagulation. Thrombosis et Diathesis Haemorrhagica 20: 15.
• 13 Stachtjrska J, Latallo Z. S, Kopec M. 1970; Inhibition of platelet aggregation by dialysable fibrinogen degradation products (FDP). Thrombosis et Diathesis Haemor- hagica 23: 91.
• 14 Takaki A, Ishiguro M, Funatstt M. 1972a Anticoagulant peptide obtained from fibrinogen degradation products by plasmin I. Isolation of the peptide. Proceedings of the Japan Academy 48: 528.
• 15 Takaki A, Yoshitake S, Ishiguro M, FuNATSi J. M. 1972b Anticoagulant peptide obtained from fibrinogen degradation products by plasmin II. Sequence determination of the peptide. Proceedings of the Japan Academy 48: 534.
• 16 Takaki A. 1973; Anticoagulant peptide obtained from fibrinogen degradation products by plasmin. Fukuoka Acta Medica 64: 243.
• 17 Wallen P, Iwanaga S. 1968; Difference between plasmi’c and tryptic digests of human S-sulfo-fibrinogen. Biochimica et Biophysica Acta 154: 414.
• 18 Yamagtjchi T. 1972; Effects of 5-hydroxytryptamine on isolated guinea pig stomach. British Journal of Pharmacology 44: 100.